Progress and prospects: immune responses to viral vectors - Wikidata - wikimedia - TriplyDB

Progress and prospects: immune responses to viral vectors

Progress and prospects: immune responses to viral vectors

http://www.wikidata.org/entity/Q28264531

about

Biomedical Application of Dental Tissue-Derived Induced Pluripotent Stem Cells Mechanisms of microbubble-facilitated sonoporation for drug and gene delivery.Adenoviral vectors for prodrug activation-based gene therapy for cancer Engineering mesenchymal stem cells for regenerative medicine and drug delivery Persistent hepatitis B viral replication in a FVB/N mouse model: impact of host and viral factors Retroviral vectors and transposons for stable gene therapy: advances, current challenges and perspectives Getting miRNA Therapeutics into the Target Cells for Neurodegenerative Diseases: A Mini-Review Improving ultrasound gene transfection efficiency by controlling ultrasound excitation of microbubbles Gene therapy of carcinoma using ultrasound-targeted microbubble destruction Gene therapy for cardiovascular disease mediated by ultrasound and microbubbles.The MRL/lpr mouse strain as a model for neuropsychiatric systemic lupus erythematosus.Poly(β-amino ester)-DNA complexes: time-resolved fluorescence and cellular transfection studies Comparative study of the transfection efficiency of commonly used viral vectors in rhesus monkey (Macaca mulatta) brains Use of Lentiviral Particles As a Cell Membrane-Based mFasL Delivery System for In Vivo Treatment of Inflammatory Arthritis.Mucosal immunization with integrase-defective lentiviral vectors protects against influenza virus challenge in mice Sustained expression of insulin by a genetically engineered sertoli cell line after allotransplantation in diabetic BALB/c mice RNAi and small interfering RNAs in human disease therapeutic applications.Modeling Pulmonary Disease Pathways Using Recombinant Adeno-Associated Virus 6.2.Prime immunization with rotavirus VLP 2/6 followed by boosting with an adenovirus expressing VP6 induces protective immunization against rotavirus in mice Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteers A composite MyD88/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy B-Cell Depletion is Protective Against Anti-AAV Capsid Immune Response: A Human Subject Case Study Pompe disease gene therapy.Shielding the messenger (RNA): microRNA-based anticancer therapies.Implications of the innate immune response to adenovirus and adenoviral vectors.Gene therapy for neuropathic pain by silencing of TNF-α expression with lentiviral vectors targeting the dorsal root ganglion in mice.Gene Therapies for Cancer: Strategies, Challenges and Successes.Lentiviral gene transfer into the dorsal root ganglion of adult rats.Induction of interferon pathways mediates in vivo resistance to oncolytic adenovirus.Improved Immunological Tolerance Following Combination Therapy with CTLA-4/Ig and AAV-Mediated PD-L1/2 Muscle Gene Transfer.Immune Responses to rAAV6: The Influence of Canine Parvovirus Vaccination and Neonatal Administration of Viral Vector Intracellular trafficking of polyamidoamine-poly(ethylene glycol) block copolymers in DNA delivery.Effective reduction of the interleukin-1β transcript in osteoarthritis-prone guinea pig chondrocytes via short hairpin RNA mediated RNA interference influences gene expression of mediators implicated in disease pathogenesis Gene therapy for haemophilia: prospects and challenges to prevent or reverse inhibitor formation.Genetically engineered immune privileged Sertoli cells: A new road to cell based gene therapy.Type I IFN induced by adenovirus serotypes 28 and 35 has multiple effects on T cell immunogenicity MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review.Off-the-shelf adenoviral-mediated immunotherapy via bicistronic expression of tumor antigen and iMyD88/CD40 adjuvant Gene therapy approaches for lysosomal storage disease: next-generation treatment.Reprogrammed quiescent B cells provide an effective cellular therapy against chronic experimental autoimmune encephalomyelitis.

P2860

Q26753857-312D2584-14AF-4197-A3B8-2B19C1B761F9 Q26859479-A7703BE0-CAE6-4A9A-A17E-D50F8AB5C8C7 Q26860729-41E0C5B6-F69C-40CD-AC90-FE1AA01840EF Q27026414-4B12398E-394F-4930-B186-7F602B2FD99C Q27302970-A3C17FE3-D7CA-4853-A596-BA613ACC0FC3 Q28074002-5A3AFCC6-254E-442E-A0C5-E6432CA5982E Q28079707-43591C7D-D942-49AC-901D-6DF60DC6F58F Q30430111-4A35592A-2002-4A9F-8A39-C9FE9F02B2F8 Q30434291-A2EED719-7C32-4BDB-A5C3-8451757037F3 Q30454594-9CAEA773-2B0B-475A-8A6D-DDB203D115A5 Q30476952-DCA1B03D-97DA-4A20-83AE-2C3848FAEE92 Q31020760-902583FB-3B15-45C8-8628-5821F5464AE2 Q33577391-5B50B595-4EA3-436C-9F48-3D0FD2237FC8 Q33586182-11798ABB-34C5-4B9B-AB3A-5952772AEF7D Q33604567-7947C163-A986-4B71-A023-921DAC45DC8F Q33826170-0A577D04-227B-4ACA-ACAB-C9DF8AE21BCE Q34204092-B0DC6A7E-5E2E-4AEF-866B-58728FE8F801 Q34470424-DA507D15-FB69-43D3-BE90-D05BD44B633F Q34510430-116C0546-A986-48BE-A14B-4F6546577D6F Q34589611-A67D3B01-C2F7-4E25-AA99-FBF460B7CAF8 Q34755217-168D79C7-AC35-423A-A1FE-866CA9E5B6EA Q34763584-272B89F7-159C-4522-B55F-F0921438BE26 Q34982843-266C1B25-78AC-4EC0-924C-85A097066AFC Q35070602-16650D4B-329C-4C0F-BD3A-D80541DBDCC2 Q35085363-49E324EC-A42E-4DEF-B3B0-8EAFE062F22E Q35123999-43E76430-9AC1-47FC-AFD8-0AB7861ECC92 Q35186312-47469D74-90B1-418B-BDC0-B0DF0076BD4A Q35231284-AF99535A-2BA7-4918-83D0-42C2FF071479 Q35285768-F1ECDDBE-3408-47F0-8BA7-8196287947DC Q35451204-C08EFAA3-322B-4DA9-899D-BF1A67D97FC4 Q35513407-AD210D03-2B1B-42CE-85F8-5BFCC2A4F2DC Q35555581-B36C01A6-9695-4C77-B513-B02E752C5136 Q35668945-FD6F2189-1FEC-4BE7-B485-F9089E91A753 Q35670173-F9C0CFA1-428E-42E7-90EB-4E9EC7427394 Q35925455-AEB03434-3D03-4AD9-9760-75E62C719383 Q36016455-59759C49-1817-4780-AA49-D97DD104F3CC Q36037933-6BAFA769-8DD1-4C5A-B092-3103C841B9A1 Q36085370-10412865-A988-42E3-AC8D-50CDF364189F Q36147475-912AD8A0-352A-4A33-BD8A-859F38C8D6D2 Q36201277-E25FB1F8-1ECF-4A9D-A17F-1EB056584E84

P2860

Progress and prospects: immune responses to viral vectors

http://www.wikidata.org/entity/Q28264531

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Progress and prospects: immune responses to viral vectors

@ast

Progress and prospects: immune responses to viral vectors

@en

Progress and prospects: immune responses to viral vectors

@nl

type

label

Progress and prospects: immune responses to viral vectors

@ast

Progress and prospects: immune responses to viral vectors

@en

Progress and prospects: immune responses to viral vectors

@nl

prefLabel

Progress and prospects: immune responses to viral vectors

@ast

Progress and prospects: immune responses to viral vectors

@en

Progress and prospects: immune responses to viral vectors

@nl

P1433

Q28264531-3BBD083C-4F07-4EC0-9412-D88A6E314CA1

P1476

Q28264531-6157BC7F-DE19-4874-9BF3-92004B71D293

P2093

Q28264531-28085653-937E-4300-B6F8-54DE150F9A93

Q28264531-740F5AAC-BA4F-402E-AFE3-57ECED41B175

P2860

Q28264531-008C2EDF-FA13-470E-BE81-5904D6075600

Q28264531-0188348F-BD14-4321-9CD9-528C00754439

Q28264531-033F0EC8-9A89-4E4A-B714-75FAFB05D1F0

Q28264531-08C8C4F4-3BFD-4CBC-B953-8EE5E0CB32D7

Q28264531-0A3CB378-FCE7-45C1-A440-75FBA40912DF

Q28264531-0AA93F2E-41F6-4088-901B-EF60A3AD052B

Q28264531-0BFA9960-95DC-4D5D-9CC7-B1F912EB0D8D

Q28264531-0EFE20F8-2CF6-4881-AB0E-292DFC8343F8

Q28264531-134AF959-F7A3-4651-8F2F-22DDFB82D2EF

Q28264531-1371A91C-57E9-44A7-9FE3-66C5F40C3B3C

P2888

Q28264531-D55237C4-FC62-4387-AE89-E9F9514F02AB

P304

Q28264531-7ABBC0F8-4131-488F-9153-42D0E4A0588C

P31

Q28264531-93CDE4A5-4A33-4141-A1E5-505D91269782

P3181

Q28264531-7BF87239-52E0-408F-A166-1C25D265205A

P356

Q28264531-33253988-DC0C-49F0-A23B-CD2264A99F72

P407

Q28264531-6D8BDFF5-1571-4EDD-B1B9-502760D2F8A2

P433

Q28264531-6AC7E7DE-71F6-4E68-831D-291B6F2561E0

P478

Q28264531-B4A03FAD-99E4-4BE0-B1EF-61835C4177CC

P577

Q28264531-B16B3DD0-19D7-4882-9C09-B70029F04C63

P6179

Q28264531-59602EEE-CC26-4FA9-88C5-79AC40633BCD

P698

Q28264531-C5DBF3F1-E7E7-4E6A-A417-274C649B0B59

P932

Q28264531-19BEC831-4DBF-4188-9C02-6C8A10DC9E05

P3181

P356

P1433

P1476

Progress and prospects: immune responses to viral vectors

@en

P2093

R W Herzog

http://www.w3.org/2001/XMLSchema#string

S Nayak

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial

Safety and efficacy of gene transfer for Leber's congenital amaurosis

Effect of gene therapy on visual function in Leber's congenital amaurosis

The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response

Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance.

Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential

Complex interactions with several arms of the complement system dictate innate and humoral immunity to adenoviral vectors.

Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy.

Tolerance induction to cytoplasmic beta-galactosidase by hepatic AAV gene transfer: implications for antigen presentation and immunotoxicity

Reduction of liver macrophage transduction by pseudotyping lentiviral vectors with a fusion envelope from Autographa californica GP64 and Sendai virus F2 domain.

P2888

P304

295-304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3032828

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/GT.2009.148

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1032028454

http://www.w3.org/2001/XMLSchema#string

P698

19907498

http://www.w3.org/2001/XMLSchema#string

P932

3044498

http://www.w3.org/2001/XMLSchema#string